FAB将急性巨核细胞白血病(AMKL)定为M7型。作者研究了1982-1986年就诊的409例急性白血病中的28例AMKL的特点。方法:(1)细胞形态学和组织化学研究,包括非特异性脂酶,α萘酚醋酸脂酶(ANAE)及α萘酚丁酸脂酶(ANBE);(2)免疫学标志,包括抗糖蛋白单克隆抗体,抗-GPⅢa(C17)及抗-GPⅡb/Ⅲa(FMC24,J15)等。结果:(1)28例AMKL中,既往患骨髓增殖性疾病,骨髓增生异常综合征,急性非淋巴细胞白血病及继发性白血病者分别占10,3,14与1例;(2)患者血红蛋白平均为8.8±2g/dl,50%患者白细胞计数<7×10~9/L,血小板正常或增高;(3)既往患白血病的AMKL患者14例,平均存活期为7.6个月,其中3例采用急性粒细 FAB defines acute megakaryoblastic leukemia (AMKL) as M7. The authors studied the characteristics of 28 AMKL cases in 409 acute leukemias treated between 1982 and 1986. Methods: (1) Morphological and histochemical studies including nonspecific lipase, alpha naphthol acetate acetate (ANAE) and alpha naphthol butyrate lipase (ANBE); (2) immunological markers including anti-sugar Protein monoclonal antibody, anti-GPIIIa (C17) and anti-GPIIb / IIIa (FMC24, J15) and so on. Results: (1) In 28 AMKL cases, there were 10, 3, 14 and 1 cases of myeloproliferative disorders, myelodysplastic syndrome, acute non-lymphocytic leukemia and secondary leukemia respectively. (2) The hemoglobin With an average of 8.8 ± 2g / dl, 50% of patients with white blood cell count <7 × 10 ~ 9 / L, normal or increased platelet; (3) 14 cases of AMKL patients with previous leukemia with an average survival of 7.6 months, of which 3 Acute granularity